Glioblastoma is considered one of the most severe malignancies in human adults. Research focusing on glioblastoma has continued for decades, with a limited number of treatments undergoing clinical trials. Recently, T cells bearing chimeric antigen receptors (CARs) have been researched intensely as a promising immunotherapeutic approach, yet dilemmas such as antigen escape, unspecific activation and immune inhibition from tumour cells are limiting their feasibility. In this work, based on the latest reports of advanced CAR T system, we designed a novel CAR T system to treat glioblastoma integrated synthetic Notch receptor, anti-p32 CAR, nuclear receptor subfamily 4A inhibition element and oxygen-dependent degradation domain. It will be activated with a gating strategy and stepwise method to promote its specificity, security and cytotoxicity, which makes it a potentially improved treatment of glioblastoma in the future.
|